Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy

Table 2

Treatment-related adverse events during TVR/PegIFN/RBV triple therapy.

	TVR/PegIFN/RBV triple therapy > 4 weeks ()
Overall treatment-related AEs during TVR/PegIFN/RBV	10 (92%)
Discontinuation of TVR/PegIFN/RBV due to AEs	1 (9%)
Anemia with hemoglobin levels below 10 g/dL	5 (45%)
EPO administration	5 (45%)
Blood transfusion	4 (36%)
Leukopenia with a WBC count below 1.5/nL	5 (45%)
GCF administration	5 (45%)
Renal failure	2 (18%)
Infection	3 (27%)
Skin changes	2 (18%)
Anorectal pruritus	1 (9%)
Death	0

TVR/PegIFN/RBV triple therapy was discontinued in 1 patient after 4 weeks due to a nonresponse.